Michelle LeRoux Williams
Known title: CHIEF SCIENTIFIC OFFICERCIK: 0001398249
Associated companies
Transaction History
| ELUT | ▲ Buy | Option Exercise | 12,500 | — | 9/10/2026 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 4,269 | $3K | 9/10/2026 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 12,500 | — | 6/10/2026 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 4,269 | $4K | 6/10/2026 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 12,500 | — | 3/10/2026 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 4,613 | $5K | 3/10/2026 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 12,500 | — | 12/10/2025 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 3,951 | $3K | 12/10/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 12,500 | — | 9/10/2025 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 3,950 | $5K | 9/10/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 12,500 | — | 6/10/2025 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 3,951 | $8K | 6/10/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 12,500 | — | 3/10/2025 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 4,613 | $14K | 3/10/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 12,500 | — | 12/10/2024 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 3,950 | $17K | 12/10/2024 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 3,951 | $16K | 9/10/2024 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 12,500 | — | 9/10/2024 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 15,800 | $45K | 8/12/2024 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 50,000 | — | 8/12/2024 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 7,900 | $27K | 6/10/2024 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 25,000 | — | 6/10/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Elutia Secures $8M from Boston Scientific, Funds Through 2029
Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.
Elutia Secures $8M from Boston Scientific, Funds Through 2029. Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.